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Summary Despite attempts to standardize tuberculosis (TB) control strategies,
there remains wide variation in the selection and implementation of control strate-
gies within and among nations. Some of this variation is appropriate; based on wide
variations in the available resources, the prevalence of TB infection, the incidence of
TB disease, the relative contribution of reactivation versus recent transmission to
incident cases, and the rate of HIV co-infection. This review will discuss three
controversial questions relevant to global TB control: (1) What is the role of the
treatment of latent TB infection in global TB control? (2) What are successful
strategies to control immigrant TB in low incidence countries? (3) What are successful
strategies to control TB in persons with HIV infection?
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Tuberculosis (TB) is the second leading cause of
death worldwide, killing around 1.8 million persons
annually.1 TB rates vary widely by region (Table 1)
with the highest case rates and mortality rates in
Africa and the lowest rates in the Americas and
Europe.1 Large discrepancies exist among the coun-
tries in each region, and among different locations
and demographic groups within each country. TB* Corresponding author. Tel.: +1 919 684 5455;
ax: +1 919 684 4288.
E-mail address: richard.frothingham@duke.edu
R. Frothingham).
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oi:10.1016/j.ijid.2005.04.001case rates have been falling steadily in many parts of
the world. However, local and regional increases in
TB cases have occurred due to limited resources,
societal disruptions and an expanding HIV epidemic.
Outbreaks due to multidrug-resistant tuberculosis
(MDR-TB) have occurred in a number of locations,
often in association with a breakdown in the health-
care infrastructure. Despite attempts to standar-
dize TB control strategies, there remains wide
variation in the selection and implementation of
control strategies within and among nations. Some
of this variation is appropriate based on wide varia-
tions in the available resources, the prevalence of
TB infection, the incidence of TB disease, the rela-
tive contribution of reactivation versus recentes. Published by Elsevier Ltd. All rights reserved.
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Table 1 Estimated TB incidence and mortality by region, 2002.
Region Number of cases (thousands) Cases per 100,000 population Deaths from TB
All forms (%) Smear-positive All forms Smear-positive Number
(thousands)
Per 100,000
population
Africa 2354 (26) 1000 350 149 556 83
The Americas 370 (4) 165 43 19 53 6
Eastern Mediterranean 622 (7) 279 124 55 143 28
Europe 472 (5) 211 54 24 73 8
South-East Asia 2890 (33) 1294 182 81 625 39
Western Pacific 2090 (24) 939 122 55 373 22
Global 8797 (100) 3887 141 63 1823 29
Data from World Health Organization1; Death statistics include TB deaths in persons infected with HIV.transmission to incident cases, and the rate of HIV
co-infection. This review will discuss three ques-
tions that are controversial and relevant to global
TB control. The goal is to consider these issues in the
context of global tuberculosis control. As a group,
the authors have provided tuberculosis care in seven
countries: Democratic Republic of Congo, Haiti,
Rwanda, Saudi Arabia, Tanzania, United States
and Zimbabwe. The authors currently practice in
the United States, so their experience is weighted
toward a North American perspective.What is the role of the treatment of
latent TB infection in global TB
control?
Controversy
There are dramatic differences of opinion among
providers in different nations related to the treat-
ment of latent TB infection (LTBI). Treatment of
LTBI has been a major component of TB control in
the United States (US) for many decades, and is
increasingly adopted in developing countries. How-
ever, the strategy has been greeted with skepticism
in many countries and often generates resistance
when offered to immigrants from developing coun-
tries. Most countries have adopted either BCG
vaccination or treatment of LTBI as a primary
strategy to prevent TB disease. The evidence for
the efficacy of the treatment of LTBI will be
reviewed, then its appropriate application as a
component of global TB control based on local
priorities and resources will be discussed.
Background
After infection, Mycobacterium tuberculosis (MTB)
may remain latent for weeks to years before caus-
ing disease. Progression to symptomatic TB diseaseoccurs only in a minority of those infected. The
condition of clinical latency in the presence of
infection with live MTB is described as latent TB
infection (LTBI). LTBI is generally demonstrated by
a positive reaction to a tuberculin skin test (TST). A
purified protein derivative from killed MTB is
injected intradermally, then induration is mea-
sured 48 to 72 hours later. Based on clinical and
epidemiological factors, varied thresholds of
5 mm, 10 mm, and 15 mm are used to interpret
the TST as positive or negative. The assumption
that a positive TST represents infection with live
MTB has been supported by the high rates of reac-
tivation in TST-positive individuals who develop
advanced immunosuppression due to HIV infection.
The goal of treatment of LTBI is to decrease the
likelihood that TB infection will progress to active
TB disease. This treatment has previously been
described as ‘preventative therapy’ or ‘prophy-
laxis’, but these terms are confusing since the
therapy does not actually prevent infection. The
goal of treatment of LTBI is eradication of an
existing asymptomatic infection in order to prevent
disease. The concept of treating LTBI has been
considered most relevant in populations where
repeated exposure to MTB is limited.
Efficacy of treatment for LTBI
Shortly after isoniazid was discovered to be bac-
tericidal for MTB, interest surged in treating those
with LTBI. A number of large clinical trials have
demonstrated that treatment of LTBI reduces, but
does not eliminate the risk of TB disease. Trials in
otherwise healthy adults enrolled huge numbers of
subjects since the background rate of progression
to disease was relatively low (Table 2). More recent
trials in persons with HIV infection have demon-
strated benefit in small populations.2,3 The relative
benefit is similar, but the absolute benefit as mea-
sured by reduction in TB incidence is much higher in
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Table 2 Efficacy of various durations of isoniazid treatment for persons with fibrotic lung lesions, International Union
Against Tuberculosis Trial, 1969—1977.
Group Five-year TB incidence per 1000 person-years (% reduction)
Placebo 12 weeks 24 weeks 52 weeks
All participants (n = 27,830) 14.3 11.3 (21) 5.0 (65) 3.6 (75)
Adherent participants (n = 21,635) 15 9.4 (31) 4.7 (69) 1.1 (93)
Fibrotic lesions <2 cm (n = 18,663) 11.6 9.2 (20) 4.0 (66) 4.2 (64)
Fibrotic lesions >2 cm (n = 8428) 21.3 16.2 (24) 7.0 (67) 2.4 (89)
Table from reference 4; Data from reference 112.
Table 3 Incidence of active tuberculosis (TB) in per-
sons with a positive tuberculin skin test, by selected
risk factors.
Risk factor TB cases/
thousand
person-years
Recent TB infection
Infection <1 year past 12.9
Infection 1—7 years past 1.6
Human immunodeficiency virus
(HIV) infection 35.0—162
Injection drug use
HIV seropositive 76.0
HIV seronegative or unknown 10.0
Silicosis 68
Radiographic findings consistent
with prior TB
2.0—13.6
Weight deviation from standard
Underweight by 15% 2.6
Underweight by 10—14% 2.0
Underweight by 5—9% 2.2
Weight within 5% of standard 1.1
Overweight by 5% 0.7
Table from reference 4.populations with a higher medical risk. Recent
trials of treatment of LTBI in persons with HIV
infection have also demonstrated the efficacy of
a number of alternative regimens.4 Isoniazid can be
given daily or twice weekly using directly observed
therapy (DOT). The preferred duration of isoniazid
therapy for treatment of LTBI is now nine months in
the US, although a six-month regimen is acceptable
for adults without HIV infection or fibrotic lung
lesions. Daily rifampin for four months is an accep-
table alternative to isoniazid.4 The combination of
rifampin and pyrazinamide for two months is effec-
tive, but is associated with a substantial risk of
hepatotoxicity.5 This regimen is no longer recom-
mended as routine treatment for LTBI, but it may
be used when a longer isoniazid regimen is not
feasible.6
Requirement for prolonged treatment
Most antituberculous medications target cell wall
or protein synthesis, and are thus most active
against actively metabolizing, cell wall-building
bacteria. Bacterial replication appears to be mark-
edly reduced during latent infection, so a latent
tubercle bacillus is less amenable to killing than an
actively replicating organism. Drug therapy for LTBI
must be given over a prolonged time period to be
effective. In persons with fibrotic lung lesions, 12
weeks of daily isoniazid therapy led to minimal
reduction in TB disease (Table 2). Extending the
duration to 24 weeks led to more reduction, but the
best results were seen when therapy was extended
to a full 52 weeks. The requirement for prolonged
therapy dampens the enthusiasm for the treatment
of LTBI. This therapy is further complicated by the
challenge of encouraging a patient who feels well
to take a drug for a potential future benefit. As
demonstrated by the sub-group analysis in Table 2,
adherent participants achieved a higher benefit
than other participants. Drug efficacy (purely the
drug’s ability to have a certain effect) is substan-
tially higher than the population effectiveness(includes the drug efficacy with issues such as
tolerability and compliance).
Groups with high risk of progression from
LTBI to TB disease
The likelihood of progression from latent infection
to active disease is highest in the first year after
infection, steadily declining with the duration of
latent infection (Table 3). It also varies greatly
among hosts based on age and underlying medical
conditions (Table 3). This has gradually diminished
the one-size-fits-all approach, but in turn has led to
more complicated criteria for the interpretation of
the TSTas a guide to the treatment of LTBI (Table 4).
Populations with exceptionally high risk of progres-
sion to active disease include young children, those
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Table 4 Criteria for tuberculin positivity, by risk group.
Reaction  5 mm induration Reaction  10 mm induration Reaction  15 mm
induration
 HIV-positive persons  Recent immigrants
(i.e., within the last 5 years)
from high prevalence countries
 Persons with no risk
factors for TB
 Recent contacts of TB case patients  Injection drug users
 Fibrotic changes on chest radiograph
consistent with prior TB
 Residents and employees of
high risk congregate settings
 Patients with organ transplants
and other immunosuppressed patients
 Mycobacteriology laboratory personnel
 Persons with the following
clinical conditions: silicosis, diabetes
mellitus, chronic renal failure, leukemia,
lymphoma, carcinoma of the head or
neck and lung, weight loss of 10% of
ideal body weight, gastrectomy, and
jejunoileal bypass
 Children younger than four years
 Infants, children, and adolescents
exposed to adults at high risk
Table condensed from reference 4.exposed in the preceding 1—2 years, and those with
silicosis, HIV infection, or other immunosuppressive
conditions (organ transplantation, treatment with
TNF-a inhibitors, etc.). Due to a high rate of pro-
gression and greater severity of TB disease, the
absolute benefit of LTBI for these groups is high.
In settings where treatment of LTBI is ongoing, or
being contemplated, there should be little disagree-
ment about recommending treatment for LTBI in
these cases.
Risks of treatment for LTBI
The US Public Health Service conducted a large trial
in the 1960s showing a risk of isoniazid-associated
hepatitis of about 1%.7,8 A later meta-analysis
revised the estimate to approximately 0.6% of
latently infected subjects.9 However, toxicity
increases with age, concomitant active hepatitis B
and alcoholism. Other adverse reactions have been
given less attention in the literature, and include
rash, GI intolerance, and headache. The fact that
people who are otherwise well are being prescribed
a medication with these side effects, which they are
asked to take for 6—9 months, leads to poor com-
pletion of therapy. A recent study from a public
health clinic in southern California found that 18%
experienced an adverse effect and only 64% com-
pleted six months of treatment.10 A shorter regimen
combining rifampin and pyrazinamide for eight
weeks was found to be effective in a population
at great risk for TB, namely those with HIV or AIDS.11
Assuming that the findings could be extrapolated tothe non-HIV-infected population, the regimen was
recommended as an option by the US Centers for
Disease Control (CDC).
When the rifampin/pyrazinamide regimen was
used in persons without HIV, an excess risk of hepa-
totoxicity was observed compared to that seen in
the HIV-positive cohort previously studied.12—15 The
incidence of hepatotoxicity when these two drugs
are used to treat LTBI also exceeds that observed
when four drugs including rifampin and pyrazina-
mide are used to treat active TB disease.16 This
paradox is the subject of much discussion within
the TB control community and studies are needed to
understand the basis of the apparent difference.17
In the meantime, the combination of rifampin
and pyrazinamide is not recommended for routine
use in the US for treatment of LTBI, but it may be
considered when the more prolonged isoniazid
treatment is not feasible.6 This experience raised
new questions about the mechanisms of drug-
induced liver injury, and the balance between risk
and benefit in persons with LTBI who do not have
medical risk factors for progression to active TB.
BCG vaccine versus LTBI treatment
Administration of BCG vaccine early in life is recom-
mended in many countries. This strategy makes
sense when TB disease remains relatively common
in the population, leading to unapparent exposure
of young children. Because children under two years
of age are at such high risk of life-threatening
disseminated disease, the benefit of BCG given to
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accepted. In addition, recent long-term follow-up
of patients vaccinated in an Alaskan Eskimo com-
munity confirms that BCG decreases the risk of TB
disease by a modest amount for many decades.18
However, in populations with limited numbers of
cases — such as in North America and Western
Europe — and where most cases of TB are identified,
a different approach has been taken. Rather than
subject an entire population to the cost and the
small but definable risks of BCG vaccine,19 the focus
is on testing for LTBI and on treating those who are
identified.4 These populations are generally also
more likely to be able to afford the healthcare
expenditure needed for testing and treating LTBI.
Since vaccination with BCG complicates the inter-
pretation of the TST, societies have tended to
choose either BCG vaccination or the strategy of
TST and treatment of LTBI. There is an increasing
body of data indicating that TSTremains informative
in persons who have previously received BCG vac-
cine.20 Recent trials of LTBI in persons with HIV
infection who were previously vaccinated with
BCG have demonstrated the validity of the TST in
predicting the risk of TB disease in this group and the
value of LTBI in reducing TB disease.2,21,22 There is
room for a dual strategy of universal BCG vaccina-
tion at birth for everyone followed by selective use
of screening and treatment of LTBI in high risk
populations. Screening and treatment for LTBI
would be especially beneficial to TST-positive adults
who are in the highest risk groups for progression to
TB disease, including those with HIV infection.
Priorities for TB control programs
The highest priority for TB control programs world-
wide must be to identify and effectively treat the
most infectious (acid-fast-smear positive) TB
cases.23 In the authors’ opinion, the next highest
priority, especially in populations with a substantial
prevalence of HIV infection, is to expand TB diag-
nostic capabilities. TB control programs need to be
supported to develop the necessary infrastructure
to provide patient-specific sputum culture and drug
sensitivity results for patients suspected of having
TB — both smear-positive and smear-negative cases.
The initial investment may focus on re-treatment of
apparent treatment failures, in order to curtail
spread of MDR TB, but should promptly move toward
including all TB suspects. In high incidence coun-
tries, widespread administration of BCG vaccine to
newborns should continue to be considered a high
priority and has likely saved many lives over the 80
years it has been in use. In populations where active
TB is relatively rare and the majority of cases arebeing found, identification and treatment of LTBI is
next in the list of overall program priorities. Tar-
geted testing and treatment of ‘high risk’ indivi-
duals, rather than mass screening, is the strategy of
choice. Persons at high risk for progression to clin-
ical TB disease include recent (<2 years) contacts to
a person with pulmonary TB,24 and children<4 years
of age or who have underlying HIV infection or other
conditions causing immunosuppression. Tracing con-
tacts to infectious TB cases, identifying secondary
active TB cases, and then testing and treating those
with LTBI due to recent infection is the kind of high-
priority, targeted activity that should speed the
decline of TB in any community.
Summary
Individual recommendations for the treatment of
LTBImust bemade by balancing the risk of TB disease
with the risk of treatment. At a countrywide or
programmatic level, the priority must be on contacts
to active cases, particularly those <4 years of age,
and thosewithHIV infection. Programs still struggling
with implementation of core TB activities — finding
all cases of active TB, providing culture and suscept-
ibility testing for the majority of suspect cases,
including those that are AFB smear-negative, assur-
ing a consistent supply of first- and second-line TB
drugs, and maintaining educated staff to oversee
prompt completion of therapy — probably need to
focus on those activities prior to implementing
targeted testing and treatment of LTBI.What are successful strategies to
control immigrant TB in low incidence
countries?
Controversy
As TB rates have declined in developing countries,
an increasing proportion of TB cases have been
attributed to immigrants from high-incidence coun-
tries. Interventions that target recent immigrants
can contribute to the health of the individual immi-
grants and to overall TB control in developing coun-
tries. However, such efforts may produce stigma and
lead to resistance from immigrant populations. Here
strategies will be discussed along with the evidence
that they have provided benefit.
Volume of migration
Migration from the resource-poor developing world
to the resource-rich developed world is occurring at
302 R. Frothingham et al.an astounding pace. Between 1995 and 2000,
approximately 2.3 million persons per year migrated
from the developing world to the developed
world.25 The US alone accepted over 1 million
immigrants in 2002 from over 200 countries.26 In
2000, approximately 1 in 13 persons residing
in Europe was born elsewhere; this was true for 1
in 8 US residents and about 1 in 5 residents of
Australia and New Zealand.25,27 Many of these
residents immigrated from the developing world;
for example, 78% of foreign-born US residents
emigrated from Latin America or Asia. In addition
to immigrants, over 32 million persons entered the
US for non-immigration visits in 2002 alone,26 some
of whom stayed for extended periods.
Impact of immigration on TB control
Immigration is a vital source of economic and cul-
tural exchange, but also results in the importation
of infectious diseases.28 TB, in particular, is
increasingly becoming an imported disease in the
developed world. Eighty percent of the estimated 8
million new cases of TB worldwide each year occur
in one of 22 high-burden developing nations.29
When persons migrate from these nations, they
often carry latent TB infection that may reactivate
after arrival in the host country. Continuing migra-
tion, coupled with decreasing TB incidence among
persons born in the developed world, has resulted
in an increasing proportion of TB cases in the
developed world attributable to persons born in
the developing world (Figure 1). In 2003, foreign-
born persons accounted for 53% of reported TB
cases in the US,30 compared with only 30% of
reported cases in 1993.31 Similar trends have been
reported in Canada,32 Western Europe,33,34 and
Australia.35Figure 1 Number of US TB cases in US-born and foreign-
born persons, 1993—2003. The absolute number of cases
in foreign-born persons has remained constant while the
number in US-born persons has fallen steadily. Successful
TB control in the US requires strategies to control immi-
grant TB in the US andUS participation in TB control in the
countries of origin. Data from the Centers for Disease
Control and Prevention (CDC).Risk of TB disease among immigrants
TB disease rates among immigrants from developing
countries are tightly correlated with rates in the
country of origin.32,36—38 For example, in some Afri-
can immigrant communities, TB annual incidence
may exceed 1000 cases per 100,000 population,39,40
compared to an incidence rate of ten per 100,000 in
many developing countries. The risk of progression
to active TB is greatest soon after arrival; approxi-
mately half the TB cases among immigrants from
endemic countries occur during the first five years
after immigration.40,41 However, the risk of progres-
sion to active TB in immigrants remains significantly
higher than that of native-born persons, even up to
20 years after immigration from an endemic coun-
try.42 Immigration therefore can have significant
long-term impact on TB case rates in the new host
country.43
TB diagnosis among immigrants
Diagnosis of TB among immigrants also presents
significant challenges to TB control efforts. For-
eign-born persons present with proportionately
more extrapulmonary TB than native-born persons
in developed countries.31 In particular, African44—46
and Asian47,48 immigrants have had significantly
higher rates of extrapulmonary TB than persons born
in developed countries, with up to 40—50% of
patients presenting with only extrapulmonary dis-
ease. A high prevalence of abnormal chest radio-
graphs in certain immigrant populations may also
complicate diagnostic efforts. For example, 51% of
Tibetan refugees, 20% of Vietnamese refugees, 20%
of Hmong refugees, and 13% of Russian refugees who
emigrated to Minnesota between 1992—1995 had
abnormal chest radiographs, and many of the
abnormalities were compatible with active or prior
TB.49 Furthermore, among the Tibetan refugees,
21% were thought to have progressive changes when
radiographs obtained in the US were compared to
radiographs obtained in India prior to immigration.
However, only 8.4% of Tibetan refugees in this study
were diagnosed with active TB.
MDR-TB among immigrants
In addition to increased diagnostic challenges posed
by a higher prevalence of extrapulmonary TB in
foreign-born persons, the treatment of foreign-born
TB cases is also more challenging because of a higher
prevalence of drug-resistant isolates. Foreign-born
patients reported between 1993—1998 in the US
who had never previously been treated for TB had
higher rates of resistance to isoniazid (11.6% vs.
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antituberculous drug (17.5% vs. 9.7%) than US-born
patients. In one study in Texas (US) the rate of multi-
drug resistant TB, defined as resistance to both
isoniazid and rifampin, was significantly higher
among foreign-born than native-born persons
(2.4% vs. 0.7%).50 A Spanish study demonstrated
that immigrants with TB in Madrid who had no prior
TB treatment had a 33% rate of resistance to any
first-line antituberculous drug, compared with a
10.7% rate among all TB patients in Madrid.46 Rates
of drug resistance among immigrant populations
reflect the rates in the countries of origin, which
are significantly higher in many developing coun-
tries than in developed countries.51
Transmission vs. reactivation as a source
of TB disease
TB among persons who recently immigrated from a
developing nation most often represents reactiva-
tion of latent disease,with infection acquired in the
country of origin. Molecular fingerprinting meth-
ods, primarily restriction fragment length poly-
morphism analysis of IS6110, have been used to
assess the extent of transmission of particular TB
isolates.52 Isolates that have the same molecular
fingerprint are presumed to be part of a cluster of
recent transmission, with one or more persons in
the cluster having transmitted infection to the
others. These molecular fingerprinting methods
have shown that most isolates from foreign-born
persons who have immigrated to developed coun-
tries are not part of a cluster,53—59 and likely repre-
sent reactivation of prior TB infection. The
proportion of foreign-born cases who were not part
of a cluster ranged from 55% in San Francisco57 to
89% in Greater Vancouver.54 This lack of clustering
among foreign-born persons suggests that immi-
grants do not transmit disease to others as fre-
quently as native-born persons. This suggestion is
supported by an analysis of MTB transmission in San
Francisco that used molecular fingerprinting com-
binedwithmathematicalmodeling.57 The transmis-
sion index, which represents the average number of
secondary TB cases caused directly or indirectly
through recent transmission by a source case, was
significantly lower for foreign-born persons (trans-
mission index = 0.21) than for native-born persons
(transmission index = 0.59).
A more complex association between foreign-
born status and TB transmission was observed in a
study in New York City examining patients diag-
nosed between 1990—1999.60 In this study, for-
eign-born persons with TB were generally less
likely to be part of a cluster (and thus have TBdisease due to recent transmission) than native-
born persons. However, this relationship was mod-
ified by human immunodeficiency virus (HIV) status.
Foreign-born TB patients who were HIV-seronega-
tive were less likely to be part of a cluster with
increasing duration of residence in the US, while
HIV-seropositive foreign-born TB cases were actu-
ally increasingly likely to be part of a cluster with
increasing duration of residence in the US. Finally,
most of the transmission that took place among the
foreign-born in the previously mentioned studies
was fromone foreign-born person to another; trans-
mission from foreign-born to native-born persons
was extremely uncommon.
Not all studies have concluded that TB transmis-
sion from immigrants is uncommon. In some rela-
tively closed immigrant communities, extensive
transmission within the community has been
detected. For example, among Senegalese immi-
grants in northern Italy, 43% of MTB strains were
clustered and therefore associated with recent
transmission.61 In another study, 33% of presumed
relapses among immigrants in northern Italy were
found to be caused by exogenous reinfection.62 As
immigrant communities integrate further with their
adopted societies, it would be expected that MTB
transmission from the foreign-born to native-born
persons will become increasingly common.33,63
Molecular fingerprinting methods are extremely
useful tools to understand the epidemiology of TB,
but these methods have limitations in assessing the
extent of transmission among immigrant popula-
tions. For example, molecular fingerprinting is often
unable to accurately assess TB transmission to young
children because of a high proportion of clinical TB
diagnoses without culture confirmation in the pedia-
tric population.64—66 Molecular fingerprinting also
only captures transmission that results in secondary
active cases of TB, and so underestimates the true
extent of transmission.
TB screening among immigrants
It is clear from the preceding discussion that TB
among immigrants from developing countries is an
important issue on the agenda of TB control for the
developed world. Screening of immigrants prior to
immigration is one of the major methods used
to attempt to find active TB cases early, and thus
to limit subsequent morbidity and transmission
to others. Many developed countries require TB
screening for those coming from developing coun-
tries. This consists of chest radiography, followed in
some countries by sputum microscopy for acid-fast
bacilli if the chest radiograph is abnormal.67—70
Persons with positive acid-fast smears are usually
304 R. Frothingham et al.not permitted to immigrate until they are no longer
infectious, as documented by negative acid-fast
smears of several consecutive sputum specimens.
However, immigrants with abnormal chest radio-
graphs but negative acid-fast sputum smears fre-
quently have active TB that may become infectious
after immigration. For example, in one study of
refugees entering the US between October 1999
and September 2000, the incidence of active TB
among persons with abnormal chest radiographs
classified as having inactive TB was 3625 per
100,000 persons, and the incidence of smear-posi-
tive (more infectious) TB was 1000 per 100,000
persons.71
Another study of immigrants with abnormal chest
radiographs but negative sputum smears in Califor-
nia reported that 3.5% of these persons presented
with active TB within one year of arrival.72 In the
Netherlands, asylum seekers with an abnormal chest
radiograph on entry had an incidence of 3704 TB
cases per 100,000 person-years during a three-year
surveillance period.73 Screening on entry effectively
reduced TB transmission in this population.69 While
it is clear that screening new immigrants for TB has a
high yield, most immigrants who will develop TB are
not captured by current screening measures. For
example, in 1995 only 11% of TB cases diagnosed in
Florida (US) among foreign-born persons were iden-
tified by overseas screening efforts.74 Reasons for
this may include the fact that an X-ray obtained
for immigration purposes can be considered ‘valid’
for 1—2 years and it is not uncommon for immigrant
hopefuls to arrive in the US, for example, months to
years after the screening X-ray was obtained. In
addition, in some countries there has been an active
black market for ‘normal’ X-rays forged with immi-
grants’ names.
Strategies for immigrant screening
Chest radiography has been shown to be a cost-
effective method to screen for active TB in persons
immigrating from high- to low-prevalence coun-
tries.75 The tuberculin skin test (TST), which detects
latent TB infection, is a considerably less cost-effec-
tive screening strategy, in part due to poor adher-
ence to chemoprophylaxis recommendations.76,77
TST to detect latent TB infection is also less cost-
effective becausemost persons with latent TB infec-
tion will never develop active TB, so many persons
need to be given chemoprophylaxis to prevent a
single case of TB. On the whole, however, neither
chest radiography nor the TST is likely to have a
significant impact on TB case rates in immigrant
populations. A significant proportion of immigrants
with abnormal chest radiographs do not present formedical evaluation after arrival in the new host
country.78 Also, many foreign-born persons with
TB who present in developed countries are either
undocumented immigrants or nonimmigrant visi-
tors79 who would not be screened through the immi-
gration process. Alternative strategies, such as
specialized screening programs for undocumented
immigrants,80,81 targeted screening in general prac-
tice settings,82 and prison-based screening pro-
grams,83 have been suggested to target persons
who would be missed by conventional immigration
screening. However, given the enormous numbers of
persons who migrate from the developing world to
the developed world each year, immigrant screening
programs based in the developed world are unlikely
to have a major impact on TB incidence rates among
immigrant populations.84
Responses to immigrant TB
TB has always been associated with stigma. Since
immigrants from the developingworld are also at risk
for discrimination, the stigma attached to TB may
raise formidable barriers to care. Immigrants may
want to avoid care for TB, based on a fear that they
will experience discrimination or isolation if they are
associated with this contagious illness. Illegal immi-
grants may fear deportation if they are found to have
TB.85 Societal awareness of a high rate of TB in
immigrants can provoke either xenophobia or com-
passionate activism. On the one hand, fear of immi-
grant TB may lead to fear of immigrants, provoking
discrimination, deportation and attempts to screen
out immigrants with TB or to reduce immigration
generally.86 All these approacheswill motivate immi-
grants to avoid healthcare. On the other hand,
awareness of TB in immigrants and their countries
of origin may compel wealthier nations to devote
resources to combating TB in the developing world.
The responses of medical providers, whether leaning
toward xenophobia or compassion, have major
impact on societal responses to immigrant TB. The
increased ease of international travel has led to
increasing recognition that infectious diseases know
no borders. Ultimately control of infectious diseases,
including TB, will require a global not an insular
response. The Global Fund to Fight AIDS, TB, and
Malaria is an example of an effective and compassio-
nate response to global infectious disease needs.87,88
Summary
TB is increasingly becoming an imported disease in
the developed world. Imported TB poses significant
challenges to clinicians, including increased diag-
nostic difficulty presented by a higher prevalence of
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difficulty caused by drug-resistant organisms.
Efforts to control this disease in developed coun-
tries must recognize the changing epidemiology of
TB and respond accordingly. While innovative
screening strategies and shortened chemoprophy-
laxis regimens are certainly needed, these efforts
are not likely to eliminate TB in the developed
world.89 In the long term, TB control in the devel-
oped world will only be achieved by controlling TB
in the developing world.What are successful strategies to
control TB in persons with HIV
infection?
Controversy
Persons with HIV infection are at increased risk for
TB infection, TB disease, and more serious disease
when compared to those without HIV infection. In
addition to the impact on the individual patient, co-
infection with HIVand TB may impact TB control in a
population. Strategies that are effective in other-
wise healthy populations do not always transfer
directly to TB control in persons with HIV infection.
Programs directed at HIV and TB may compete for
precious resources in developing countries.
Background
It is estimated that 50% of the population of sub-
Saharan Africa is latently infected with TB.90 Once
infected with MTB, progressive deterioration of cell-
mediated immunity caused by HIV infection
increases the risk of TB disease by a hundred-fold
or more.91,92 In 1999, the WHO estimated that 11.8
million people were living with HIV/MTB co-infec-
tion, the majority being in sub-Saharan Africa. Once
active TB develops, MTB is a potent and virulent
pathogen that spreads readily to others with HIV
infection, even causing re-infection in those who
have completed TB treatment.93 TB is clearly the
most significant AIDS-associated opportunistic
infection that can be transmitted to those without
HIV infection. Because the AIDS epidemic is most
severe in regions of the world that also have the
highest rates of TB latent infection, the TB epidemic
is also expanding in these locations.
Impact of TB on HIV infection
TB hastens immune deterioration in those with
HIV infection.94 The timing of the initiation ofantiretroviral therapy in patients with HIV/TB co-
infection is also difficult. Rifampin, a pivotal part of
TB treatment,93 reduces the level of many antire-
troviral drugs. Also, an immune reconstitution syn-
drome may occur with successful HIV therapy. The
signs and symptoms of immune reconstitution
resemble those of active TB disease, raising the
specter of TB treatment failure.95,96
Impact of HIV infection on TB
HIV infection significantly increases TB-associated
mortality.97—99 Only rapid diagnosis and TB treat-
ment can reduce this mortality. Those with active TB
and HIV infection are more likely to develop drug-
resistant TB.100,101 Laboratory resources for rapid
drug-susceptibility testing are particularly impor-
tant for this group.
Edlin et al. described 18 AIDS patients with TB
resistant to at least isoniazid and streptomycin.102
Those who received appropriate therapy within two
weeks of diagnosis had a survival of 86%, compared
to 18% among those who did not ( p = 0.01). Persons
with HIV infection are also at risk for disseminated
infection with Mycobacterium avium complex,
Mycobacterium kansasii, and other nontuberculous
mycobacteria (NTM). Unfortunately, laboratory
resources for the diagnosis of MTB and the distinc-
tion between MTB and NTM are severely limited in
the resource-limited countries most profoundly
affected by TB and HIV co-infection. The vast major-
ity of TB cases in the developing world are diagnosed
on the basis of sputum smear microscopy alone.
Reliance on the sputum smear alone may result in
missing the diagnosis in up to 50% of TB patients who
are smear-negative, or may lead to inaccurate
treatment for TB in persons with HIV who have other
mycobacterial pathogens.103 Lack of laboratory
diagnostic capacity leads to poor clinical outcomes,
prevents epidemiologic assessment of mycobacter-
ial disease in the region and may preclude initiation
or participation in meaningful clinical or transla-
tional research.
Efficacy of the treatment of LTBI in
persons with HIV infection
Treatment of LTBI has similar relative efficacy in
patients with or without HIV. Treatment reduces
the active TB rate in TST-positive HIV-infected
adults by 60—80% (Table 5).104 Since the absolute
risk of active TB is much higher in persons with HIV
infection, the absolute benefit in this population
is high. Trials of treatment of LTBI in persons with
HIV infection have been carried out in a wide
variety of settings, including countries in which
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Table 5 Prospective randomized trials of preventative TB therapy among persons infected with HIV.
Location
(reference no.)
TST status of
study subjects
Preventative treatment
regimen
TB rate
per 100
person-years
Relative risk
of TB (95% CI)
Haiti 2 TST positive (n = 25) 12 months of placebo; daily 10.0 5.8 (1.2—28.7)
TST positive (n = 38) 12 months of INH; daily 1.7 1
TST negative (n = 35) 12 months of placebo; daily 5.7 1.8 (0.4—9.2)
TST negative (n = 20) 12 months of INH; daily 3.2 1
Haiti 105 TST positive (n = 370) 6 months of INH;
two times a week
1.7 1
TST positive (n = 380) 2 months of RIF,PZA;
two times a week
1.8 1.1
Uganda3 TST positive (n = 464) 6 months of placebo; daily 3.4 1
TST positive (n = 536) 6 months of INH; daily 1.1 0.3 (0.1—0.8)
TST positive (n = 556) 3 months of INH,RIF; daily 1.3 0.4 (0.2—0.9)
TST positive (n = 462) 3 months of INH,RIF,PZA; daily 1.7 0.4 (0.2—0.9)
Anergic (n = 323) 6 months of placebo; daily 3.1 1
Anergic (n = 395) 6 months of INH; daily 2.5 0.7 (0.3—1.9)
Zambia22 TST positive (n = 60) 6 months of placebo;
two times a week
9.8 1
TST positive (n = 52) 6 months of INH;
two times a week
2.3 0.3 (0.05—1.4)
TST positive (n = 49) 3 months of RIF,PZA;
two times a week
2.7 0.3 (0.05—1.4)
TST negative (n = 166) 6 months of placebo;
two times a week
3.1 1
TST negative (n = 178) 6 months of INH;
two times a week
2.5 0.9 (0.31—2.4)
TST negative (n = 173) 3 months of RIF,PZA;
two times a week
3.8 1.3 (0.50—3.2)
Kenya21 TST positive (n = 67) 6 months of placebo; daily 8.0 1
TST positive (n = 69) 6 months of INH; daily 5.6 0.6 (0.2—1.6)
TST negative (n = 235) 6 months of placebo; daily 2.7 1
TST negative (n = 224) 6 months of INH; daily 3.3 1.2 (0.6—2.7)
United States113 Anergic (n = 257) 6 months of placebo; daily 0.9 1
Anergic (n = 260) 6 months of INH; daily 0.4 0.5 (0.1—1.9)
Multinational 11 TST positive (n = 792) 12 months of INH; daily 1.1 1
TST positive (n = 791) 2 months of RIF,PZA; daily 0.8 0.72 (0.40—1.31)
Table updated from reference 114; CI, confidence interval; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin; TST, tuberculin
skin test.BCG vaccination is administered routinely at birth.
The TST remains informative in adults who
received BCG vaccination as children. The rates
of TB disease were higher in subjects with a posi-
tive TST than in those with a negative TST.2,21,22
Furthermore, treatment of LTBI remains effective
in lowering the rate of TB infection in adults with
HIV infection and positive TSTwho received BCG as
children. Several studies in persons with HIV infec-tion demonstrate that two or three months of
combination therapy with rifampin and pyrazina-
mide had equal efficacy to six or twelve months of
isoniazid.11 The combination of rifampin and pyr-
azinamide appears to have less hepatotoxicity in
persons with HIV infection than in non-HIV-infected
populations, based on comparisons between ran-
domized controlled trials in persons with HIV infec-
tion and later clinical experience in persons
Current issues in global tuberculosis control 307without HIV infection.6,11,15,16,22,105 The rifampin/
pyrazinamide regimen for treatment of LTBI is not
recommended for routine use in the US either for
HIV-positive or HIV-negative persons,17 but it may
be considered when the more prolonged isoniazid
treatment is not feasible.6
Challenges to the use of LTBI in persons
with HIV infection
There are a number of challenges associated with
diagnosis and treatment of LTBI in patients with HIV
infection. First, the diagnosis of LTBI using the TST is
less sensitive when the CD4 count falls below about
200 cells  106/L at which time the person’s cell-
mediated immunity has often deteriorated to the
point of anergy. New serum tests based on release of
interferon-g after in vitro stimulation with MTB
specific antigens may help in this regard, but pub-
lished studies have not yet demonstrated this. In
countries where up to 50% of the population is
thought to be infected with TB, some have advo-
cated treating all patients with HIV infection for
LTBI. However, as can be seen in Table 5, anergic
patients and others with negative TST did not ben-
efit significantly, and there are major program costs
associated with this response. On the other hand,
high TB incidence rates increase the likelihood of
exogenous reinfection, raising the question of
whether treatment of LTBI should be prolonged,
either as a lifelong strategy or until antiretroviral
therapy results in immune reconstitution.106,107
Application of these strategies will depend on local
TB incidence and the availability of resources.
Treatment for LTBI in persons with HIV infection
and a positive TST has clear value, but may not
reach a high enough priority to warrant expendi-
tures if core TB program activities have not been
met.
Effect of highly-active antiretroviral
therapy (HAART) on TB
HAART impedes HIV replication, leading to a reduc-
tion in HIV viral load. The degree of viral load
suppression correlates with eventual immune recon-
stitution and an increase in CD4 lymphocyte count.
Numerous studies have shown that the incidence of
opportunistic infections due to both MTB and the M.
avium complex declines dramatically as immune
reconstitution becomes established.108—110 Though
of great importance to the individual patient,
HAART alone has limited impact on the population
incidence of TB disease among persons with HIV
infection. Dye and colleagues used a cohort analysis
approach to predict the effect of antiretroviraltherapy as a means of TB control in a high-incidence
region such as sub-Saharan Africa.111 They found
that HAARTalone, if started at the currently-recom-
mended CD4 count of 200 or less, would reduce the
cumulative incidence of TB by only 22% over 20
years. Only by starting HAART at a much higher
CD4 count, and combining it with treatment of LTBI
could the TB incidence be reduced by an estimated
70% in HIV-infected persons.
Summary
Global TB control in 2004 relies on the same basic
tools that have been used for decades: aggressive
case-finding plus organized and consistently funded
public health treatment centers that administer and
closely monitor adherence to a 3- or 4-drug treat-
ment plan. Components that are standard in devel-
oped countries need to be implemented in
developing countries: sputum culture, susceptibility
testing, and individual treatment plans that are
guided by these results.
New challenges including global population mobi-
lity, HIV infection, limited resources, and drug resis-
tance will require flexibility in the precise
application of these TB control tools in different
locales. TB control officers in different countries
have much to learn from one another about strate-
gies that succeed and those that do not. Effective TB
control requires a mixture of medical expertise and
compassionate activism.Acknowledgements
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